Online citations, reference lists, and bibliographies.
← Back to Search

Extrapleural Pneumonectomy, Photodynamic Therapy And Intensity Modulated Radiation Therapy For The Treatment Of Malignant Pleural Mesothelioma

K. Du, S. Both, J. Friedberg, R. Rengan, S. Hahn, K. Cengel
Published 2010 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Intensity modulated radiation therapy (IMRT) has recently been proposed for the treatment of malignant pleural mesothelioma (MPM). Here, we describe our experience with a multimodality approach for the treatment of mesothelioma, incorporating extrapleural pneumonectomy, intraoperative photodynamic therapy and postoperative hemithoracic IMRT. From 2004-2007, we treated 11 MPM patients with hemithoracic IMRT, 7 of whom had undergone porfimer sodium-mediated PDT as an intraoperative adjuvant to surgical debulking. The median radiation dose to the planning treatment volume (PTV) ranged from 45.4-54.5Gy. For the contralateral lung, V20 ranged from 1.4 - 28.5%, V5 from 42 - 100%, and MLD from 6.8 - 16.5Gy. In our series, 1 patient experienced respiratory failure secondary to radiation pneumonitis that did not require mechanical ventilation. Multimodality therapy combining surgery with increased doses of radiation using IMRT, and newer treatment modalities such as PDT, appears safe. Future prospective analysis will be needed to demonstrate efficacy of this approach in the treatment of malignant mesothelioma. Efforts to reduce lung toxicity and improve dose delivery are needed and provide the promise of improved local control and quality of life in a carefully chosen multidisciplinary approach.
This paper references
10.1016/J.IJROBP.2007.03.011
Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma.
D. Rice (2007)
10.1016/S0360-3016(01)02589-5
Lethal pulmonary complications significantly correlate with individually assessed mean lung dose in patients with hematologic malignancies treated with total body irradiation.
A. Della Volpe (2002)
10.1016/J.IJROBP.2006.03.012
Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma.
A. Allen (2006)
10.1016/J.IJROBP.2005.03.026
Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study.
E. Yorke (2005)
10.1016/J.ATHORACSUR.2007.04.076
Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma.
D. Rice (2007)
10.1067/MTC.2001.116560
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
10.1016/S0003-4975(02)04474-0
A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma.
J. Friedberg (2003)
10.1016/J.IJROBP.2006.07.1337
Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT).
S. Wang (2006)
10.1016/J.IJROBP.2006.09.005
Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma: in regard to Allen et al. (Int J Radiat Oncol Biol Phys 2006;65:640-645).
R. Komaki (2006)
10.1016/S0003-4975(96)01228-3
Patterns of failure after trimodality therapy for malignant pleural mesothelioma.
E. Baldini (1997)
10.1016/S0360-3016(02)04150-0
Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation.
K. Forster (2003)
10.1016/j.ijrobp.2007.11.011
Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience.
E. Miles (2008)
10.1200/JCO.2004.07.097
Phase II trial of pleural photodynamic therapy and surgery for patients with non-small-cell lung cancer with pleural spread.
J. Friedberg (2004)
10.1016/S0360-3016(02)04151-2
Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma.
A. Ahamad (2003)
10.1097/JTO.0b013e3181b9eb85
Hemithoracic Radiotherapy After Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma: A Dosimetric Comparison of Two Well-Described Techniques
C. Hill-Kayser (2009)
10.1053/J.SEMINONCOL.2005.03.009
Non-small cell lung cancer therapy-related pulmonary toxicity: an update on radiation pneumonitis and fibrosis.
F. Kong (2005)
10.1007/s002680020021
Treatment of Malignant Mesothelioma
M. D. Michael T. Jaklitsch (2001)
10.1016/S0360-3016(03)00287-6
Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma.
S. Yajnik (2003)



This paper is referenced by
10.1111/php.13225
In vivo Tissue Evaluation Reveals Improvements in Explicit PDT Dosimetry
A. Greer (2020)
10.1007/978-3-319-40618-3_37
Malignant pleural mesothelioma.
D. Ettinger (2012)
10.1016/B978-0-323-24098-7.00046-0
Chapter 46 – Uncommon Thoracic Tumors
J. Zeng (2016)
10.1111/php.13176
Reactive Oxygen Species Explicit Dosimetry for Photofrin‐mediated Pleural Photodynamic Therapy
Y. Ong (2019)
10.3390/ijms17010135
Photodynamic Therapy in Non-Gastrointestinal Thoracic Malignancies
Biniam Kidane (2016)
10.1002/mc.22986
Transglutaminase 2 takes center stage as a cancer cell survival factor and therapy target
R. Eckert (2019)
10.1245/s10434-019-07235-9
The Role of Adjuvant Radiotherapy in the Treatment of Pleural Mesothelioma
G. Lewis (2019)
10.1111/php.13166
Evaluation of Light Fluence Distribution Using an IR Navigation System for HPPH‐mediated Pleural Photodynamic Therapy (pPDT)
Timothy C. Zhu (2019)
10.2995/JACSURG.25.687
胸膜中皮腫の外科治療を巡る諸問題 : EPPかP/Dか
坪田 紀明 (2011)
10.1016/j.pneumo.2012.12.003
Prise en charge diagnostique et thérapeutique du mésothéliome pleural malin
J. Delourme (2013)
10.1016/j.athoracsur.2014.12.077
Intrapleural Photodynamic Therapy for Mesothelioma: What Place and Which Future?
C. Munck (2015)
10.1007/978-3-319-28761-4_20
Modern Radiotherapy Techniques in Malignant Pleural Mesothelioma
G. Ozyigit (2016)
10.1016/J.CANRAD.2013.06.045
Tomothérapie hélicoïdale dans le traitement du mésothéliome pleural malin : impact des faibles doses sur la toxicité pulmonaire et œsophagienne
J. Hélou (2012)
PROGNOSTIC FACTORS IN MALIGNANT PLEURAL MESOTHELIOMA
FATTORI PROGNOSTICI (2012)
10.1117/12.2525619
Reactive oxygen species explicit dosimetry for Photofrin-mediated pleural photodynamic therapy
Y. Ong (2019)
10.1053/j.seminoncol.2014.09.017
Photodynamic therapy for lung cancer and malignant pleural mesothelioma.
C. Simone (2014)
10.2741/E677
Electroporation as a strategy to promote HtrA1 gene uptake and chemotherapy efficacy in a mouse model of mesothelioma.
E. P. Spugnini (2013)
10.1016/S1470-2045(17)30459-X
Radiotherapy for the treatment of malignant pleural mesothelioma.
M. Perrot (2017)
10.1097/JTO.0b013e3182199819
Intensity-Modulated Radiotherapy After Extrapleural Pneumonectomy in the Combined-Modality Treatment of Malignant Pleural Mesothelioma
A. Chi (2011)
La thérapie photodynamique : état de l'art et perspectives
C. Frochot (2015)
10.1111/php.13065
A Novel Prospective Study Assessing the Combination of Photodynamic Therapy and Proton Radiation Therapy: Safety and Outcomes When Treating Malignant Pleural Mesothelioma
S. Rice (2019)
10.1016/j.ijpharm.2016.06.009
Berberine as a photosensitizing agent for antitumoral photodynamic therapy: Insights into its association to low density lipoproteins.
Nathalia Luiza Andreazza (2016)
10.1016/B978-1-4377-1637-5.00044-4
Uncommon Thoracic Tumors
R. Rengan (2011)
10.2174/9781681081946116010023
PROGNOSTIC FACTORS IN MALIGNANT PLEURAL MESOTHELIOMA
Tommaso Claudio Mineo and Vincenzo Ambrogi (2016)
10.1111/ajco.12680
Intensity modulated radiation therapy after extra‐pleural pneumonectomy for malignant pleural mesothelioma is feasible without fatal pulmonary toxicity and provides good survival
Sameer Jhavar (2018)
10.1016/j.pdpdt.2018.03.005
Titania and silica nanoparticles coupled to Chlorin e6 for anti-cancer photodynamic therapy.
Z. Youssef (2018)
Semantic Scholar Logo Some data provided by SemanticScholar